Why This Statin-Free Cholesterol Supplement Failed

Statin intolerance creates a real treatment problem, but it also creates a lucrative market for supplements that promise a gentler way to lower cholesterol. One 12-week placebo-controlled trial tested a monacolin K-free combination of phytosterols, bergamot, olive extract, and vitamin K2. It lowered neither LDL cholesterol nor inflammatory markers better than placebo.

The result matters because the formula was not a fair test of the ingredients at doses known to work. Its 400 mg daily phytosterol dose was far below the roughly 2 g daily threshold supported by clinical evidence. This was not proof that every nutraceutical fails. It was evidence that this particular product, at these particular doses, did not deliver a measurable benefit.

A placebo-controlled test with a uniformly null result

In a 2022 randomized, double-blind, placebo-controlled trial by Protic et al., 125 adults with mild-to-moderate hypercholesterolemia took either placebo or a daily combination of 400 mg phytosterols, 100 mg Citrus bergamia extract, 20 mg olive fruit extract, and 52 µg vitamin K2 for 12 weeks. Participants began with total cholesterol between 200 and 250 mg/dL, with a mean near 228 mg/dL.

LDL-C was the primary endpoint. The investigators also measured total cholesterol, triglycerides, HDL-C, high-sensitivity C-reactive protein, IL-32, IL-38, and several inflammatory microRNAs. The active formula produced no statistically significant advantage over placebo on any of those outcomes.

This was not a tiny exploratory study that could not distinguish signal from noise. The trial was designed with 85% power, at an alpha of 0.05, to detect a clinically meaningful LDL-C difference. That does not prove the formula had exactly zero biological activity. It does mean the study had a good chance of detecting a meaningful LDL-C effect at the dose and in the population tested. It found none.

The phytosterol dose explains much of the result

Phytosterols can lower LDL-C, but the dose does the work. In Cicero et al.'s 2023 DESCO analysis, a meta-analysis of 13 randomized trials found that phytosterol supplementation at doses of at least 2 g per day reduced LDL-C by a mean 12.14 mg/dL (95% CI, 8.98 to 15.29 mg/dL). The effect was larger when baseline LDL-C exceeded 140 mg/dL.

The Protic formula supplied 400 mg daily: one-fifth of 2 g. At that dose, the null result is unsurprising. The participants' mean total cholesterol also suggests that many may have had LDL-C near the lower end of the range where phytosterols produce the largest absolute reductions. A low dose and a less favorable baseline profile can shrink the expected effect twice.

This distinction prevents an easy but wrong conclusion. The study refutes the tested formula as an LDL-lowering treatment. It does not refute adequately dosed phytosterols as a category. A 2021 review of systematic reviews and meta-analyses likewise found that food-based LDL interventions depend heavily on the compound and the dose. "Natural" is not a dosage unit.

Other supplements have also struggled against placebo

The Protic trial does not stand alone. In a 2023 randomized trial by Laffin et al., adults with elevated LDL-C received low-dose rosuvastatin, placebo, or one of several common dietary supplements, including plant sterols. The supplement arms did not differ statistically from placebo for LDL-C reduction, while low-dose rosuvastatin significantly lowered LDL-C.

That comparison does not mean every supplement has the same effect, or that a prescription drug is automatically right for every person. It does show why labels and ingredient lists cannot substitute for controlled evidence. A bottle can contain plant sterols and still provide too little of them, combine them with poorly characterized extracts, or rely on outcomes that matter less than LDL-C and cardiovascular events.

Bergamot evidence is formulation-specific

Bergamot is the main reason not to turn this article into a blanket indictment of every ingredient in the formula. In the 2022 ANEMONE placebo-controlled trial, people with polygenic hypercholesterolemia and LDL-C of 115 to 190 mg/dL received a proprietary bergamot polyphenolic phytosome formulation plus artichoke extract. The active arm showed statistically significant improvements in lipid and inflammatory measures.

ANEMONE did not test the same intervention as Protic et al. It used a bioavailability-enhanced bergamot phytosome, not 100 mg of crude bergamot extract, and it included artichoke extract, which has independent LDL-C-lowering evidence. Those differences prevent a clean claim that bergamot alone caused the result. They also prevent positive results with the proprietary combination from validating a generic, lower-dose bergamot product.

The two trials therefore point in the same practical direction: formulation, dose, and population determine whether an ingredient list means anything. They should not be averaged into a vague verdict on "bergamot."

For confirmed statin intolerance, patient outcomes matter more

True pharmacologic statin intolerance appears less common than statin discontinuation. Morton et al. estimated in 2025 that about 1 in 11 patients, or roughly 9%, are truly statin-intolerant. The authors also noted evidence that 30% to 50% of real-world statin discontinuations may reflect nocebo effects. A clinician can help distinguish a reproducible adverse drug effect from a symptom that has another cause; that process may include rechallenge or a different statin strategy.

People who remain unable to take statins and have meaningful cardiovascular risk need options that do more than move a laboratory number. In the CLEAR Outcomes program, bempedoic acid was studied in approximately 14,000 confirmed statin-intolerant patients. Lincoff et al.'s 2024 analysis reported a 21% LDL-C reduction and a statistically significant 13% relative reduction in major adverse cardiovascular events versus placebo. Relative risk reductions need absolute event rates to show an individual's expected benefit, and those figures depend on baseline risk. Still, this is cardiovascular-outcomes evidence in the population at issue, which no nutraceutical combination in this discussion has supplied.

Bempedoic acid requires hepatic activation and is inactive in skeletal muscle, a mechanism that may help avoid the muscle symptoms that drive many cases of statin intolerance. In a prespecified CLEAR Outcomes analysis, Ray et al. found no increased risk of new-onset diabetes with bempedoic acid. Medication choice still requires an individualized conversation about risks, interactions, cost, and the full treatment plan.

What this evidence supports

The tested monacolin K-free formula did not lower LDL-C or inflammatory markers better than placebo over 12 weeks. Its phytosterol dose was too low to test the effect seen with adequately dosed phytosterols.

For a low-risk person with mild hypercholesterolemia who declines medication, phytosterols at at least 2 g daily have evidence for a modest LDL-C reduction—about 12 mg/dL on average in the DESCO meta-analysis. That is a legitimate, limited role. It is not evidence that a 400 mg blend can manage cardiovascular risk.

For someone with confirmed statin intolerance and elevated cardiovascular risk, a supplement should not replace clinical evaluation and evidence-based LDL-lowering therapy. The Protic trial gives a simple reason: when a product fails a powered placebo-controlled test at the dose sold, the marketing story has already outrun the data.